Table 4 Estimates from a hierarchical Bayesian model of the sustained virological response rates at 4 weeks (SVR4) and at 12 weeks (SVR12) after completing therapy with daclatasvir and sofosbuvir, with or without ribavirin
Estimate | SVR4 | SVR12 | ||||||
|---|---|---|---|---|---|---|---|---|
As-treated | Intent-to-treat | As-treated | Intent-to-treat | |||||
Country | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI |
Austria | 97 | 87–100 | 92 | 81–99 | 98 | 89–100 | 88 | 75–96 |
Denmark | 93 | 77–100 | 88 | 73–97 | 98 | 89–100 | 87 | 73–95 |
Spain | 98 | 95–100 | 92 | 95–100 | 98 | 94–100 | 89 | 83–94 |
Sweden | 96 | 79–100 | 90 | 73–100 | 97 | 85–100 | 87 | 72–96 |
Switzerland | 82 | 56–97 | 82 | 59–94 | 82 | 57–97 | 84 | 64–93 |
UK | 96 | 80–100 | 82 | 52–95 | 97 | 83–100 | 82 | 56–93 |
Overall | 96 | 86–100 | 89 | 76–96 | 97 | 89–100 | 87 | 75–94 |